FK506 and rapamycin: novel pharmacological probes of the immune response.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  TIPS - Trends in Pharmacological Sciences

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0165-6147(91)90555-7PMID 1710854
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of FKBP rotamase activity by immunosuppressant FK506: twisted amide surrogate.

  1990cited by this paper
• Probing immunosuppressant action with a nonnatural immunophilin ligand

  1990cited by this paper
• Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin.

  1990cited by this paper
• Kidney transplantation under FK 506.

  1990cited by this paper
• Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin.

  1990cited by this paper
• Substrate specificities of the peptidyl prolyl cis-trans isomerase activities of cyclophilin and FK-506 binding protein: evidence for the existence of a family of distinct enzymes.

  1990cited by this paper
• The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes.

  1990cited by this paper
• CYCLOSPORINE, FK506, AND RAPAMYCIN: SOME EFFECTS ON EARLY ACTIVATION EVENTS IN SERUM‐FREE, MITOGEN‐STIMULATED MOUSE SPLEEN CELLS

  1990cited by this paper
• The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors.

  1990cited by this paper
• A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection.

  1990cited by this paper
• Sensitivity of intracellular signals responsible for cell cycle progression to cyclosporine.

  1990cited by this paper
• Peptidyl-prolyl cis-trans-isomerase from Escherichia coli: a periplasmic homolog of cyclophilin that is not inhibited by cyclosporin A.

  1990cited by this paper
• Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction.

  1990cited by this paper
• Complementary DNA encoding the human T-cell FK506-binding protein, a peptidylprolyl cis-trans isomerase distinct from cyclophilin.

  1990cited by this paper
• The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells.

  1990cited by this paper
• The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes.

  1989cited by this paper
• FK 506 for liver, kidney, and pancreas transplantation.

  1989cited by this paper
• Rapamycin for immunosuppression in organ allografting.

  1989cited by this paper
• Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes.

  1989cited by this paper
• Sensitivity to cyclosporin A is mediated by cyclophilin in Neurospora crassa and Saccharomyces cerevisiae

  1989cited by this paper
• Peptidyl-prolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin

  1989cited by this paper
• A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase

  1989cited by this paper
• A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin

  1989cited by this paper
• Immunopharmacology of FK-506.

  1989cited by this paper
• Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins

  1989cited by this paper
• Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506.

  1989cited by this paper
• Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506.

  1989cited by this paper
• Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus.

  1989cited by this paper
• Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation.

  1989cited by this paper
• Two episodes of calcium uptake associated with T-lymphocyte activation.

  1988cited by this paper
• Early signal transduction by the antigen receptor without commitment to T cell activation.

  1988cited by this paper
• Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction.

  1988cited by this paper
• T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression

  1987cited by this paper
• Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation.

  1987cited by this paper
• FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

  1987cited by this paper
• FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics.

  1987cited by this paper
• Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression.

  1986cited by this paper
• Antigen-dependent increase in cytosolic free calcium in specific human T-lymphocyte clones

  1985cited by this paper
• Cyclophilin: a specific cytosolic binding protein for cyclosporin A.

  1984cited by this paper
• Induction of DNA synthesis in isolated nuclei by cytoplasmic factors from spontaneously proliferating and mitogen-activated lymphoid cells.

  1982cited by this paper

• Ndufs4 knockout mouse models of Leigh syndrome: pathophysiology and intervention

  2021cites this paper
• The Hutchinson-Gilford Progeria Syndrome and Treatment: Updated Review of the Literature

  2020cites this paper
• The road ahead for health and lifespan interventions.

  2020cites this paper
• 8.16 – Calcium and Proteases☆

  2018cites this paper
• DVT: A New Era in Anticoagulant Therapy SERCA2b Activity Is Regulated by Cyclophilins in Human Platelets

  2017cites this paper
• Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria‐related disorders

  2016cites this paper
• Dose optimization of tacrolimus for improving survival time of PEGylated islets in a rat-to-mouse xenograft model

  2016cites this paper
• Peptidyl-prolyl isomerases: a full cast of critical actors in cardiovascular diseases.

  2015cites this paper
• Comparison of reendothelialization and neointimal formation with stents coated with antibodies against endoglin and CD34 in a porcine model

  2015cites this paper
• Dynamic control of the prolyl isomerase function of the dual-domain SlyD protein.

  2013cites this paper
• Suppression of neointimal hyperplasia by sirolimus-eluting expanded polytetrafluoroethylene (ePTFE) haemodialysis grafts in comparison with paclitaxel-coated grafts.

  2012cites this paper
• Corticosteroid-sparing agents: conventional systemic immunosuppressants.

  2012cites this paper
• The role of small molecules in musculoskeletal regeneration.

  2012cites this paper
• Immunophilins and cardiovascular complications.

  2011cites this paper
• syndrome discrete from that observed with cyclosporin A disease mortality by rapamycin leads to a clinical-pathological In vivo inhibition of cytokine responsiveness and graft-versus-host

  2011cites this paper
• CCR3 and Choroidal Neovascularization

  2011cites this paper
• Frontier of Epilepsy Research - mTOR signaling pathway

  2011cites this paper
• DVT: a new era in anticoagulant therapy.

  2010cites this paper
• Calcium and Proteases

  2010cites this paper
• CHARACTERIZING AND TREATING THE NEUROPATHOLOGY OF TUBEROUS SCLEROSIS COMPLEX IN THE MOUSE

  2010cites this paper
• SERCA2b Activity Is Regulated by Cyclophilins in Human Platelets

  2010cites this paper
• Natural products AKTing on signal transduction pathways-molecules and methods

  2009cites this paper
• The effect of two novel C-type lectins, Ba100 and Ba25, isolated from the venom of the puff adder, Bitis arietans on T lymphocyte proliferative responses

  2008cites this paper
• Functional Drift of Sequence Attributes in the FK506-Binding Proteins (FKBPs)

  2008cites this paper
• Sirolimus-eluting coronary stents: a review

  2007cites this paper
• Revisão do stent coronário com eluição de sirolimus

  2007cites this paper
• The mTOR/p70S6K Signal Transduction Pathway Plays a Role in Cardiac Hypertrophy and Influences Expression of Myosin Heavy Chain Genes in vivo

  2004cites this paper
• Dose-dependent pharmacokinetics of rapamycin-28-N,N-dimethylglycinate in the mouse

  2004cites this paper
• A note on clustering the functionally-related paralogues and orthologues of proteins: a case of the FK506-binding proteins (FKBPs)

  2004cites this paper
• The suppressive effect of triptolide on experimental autoimmune uveoretinitis by down-regulating Th1-type response.

  2003cites this paper
• Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase.

  2003cites this paper
• Analogues de Rapamycine

  2003cites this paper
• Rapid synthesis of α-ketoamides using microwave irradiation–simultaneous cooling method

  2003cites this paper
• The History Of Liver And Renal Transplantation

  2002cites this paper
• Mycophenolate mofetil treatment accelerates recovery from experimental allergic encephalomyelitis.

  2001cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2001cites this paper
• Progress in renal transplantation for children.

  2000cites this paper
• Participation of a MEK-independent pathway in MAP kinase activation and modulation of cell growth in mouse hepatoma cell lines.

  2000cites this paper
• ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1.

  1999cites this paper
• Current and future modalities for functional renal replacement.

  1999cites this paper
• Cyclosporine/tacrolimus (FK-506)

  1998cites this paper
• Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse.

  1998cites this paper
• Evidence that SMS 201-995 enhances the immunosuppressive effect of FK506.

  1998cites this paper
• Current advances in the therapy of chronic renal failure and end stage renal disease.

  1998cites this paper
• Immunosuppression and Treatment of Rejection

  1998cites this paper
• FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse.

  1998cites this paper
• In vitro effects of retinoids on mitogen-induced peripheral blood leucocyte responses

  1998cites this paper
• Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase.

  1997cites this paper
• Aldosterone and dexamethasone stimulate calcineurin activity through a transcription-independent mechanism involving steroid receptor-associated heat shock proteins.

  1997cites this paper
• Expression and function of calcineurin in the mammalian nephron: physiological roles, receptor signaling, and ion transport.

  1997cites this paper
• Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from The Eastern Cooperative Oncology Group (ECOG)

  1997cites this paper
• Molecular mechanisms of the immunosuppressive action of cyclosporin A.

  1997cites this paper
• Pharmacological characterization of Sephadex-induced oedema in rat paws: predominant role of serotonin and platelet-activating factor.

  1996cites this paper
• Combination of Vitamin D Analogues and Immunosuppressants

  1996cites this paper
• In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A.

  1996cites this paper
• Progress in renal transplantation for children.

  1996cites this paper
• New drugs for asthma

  1996cites this paper
• New and experimental therapies for treating graft-versus-host disease.

  1995cites this paper
• Patent Update: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Anti-inflammatory patent highlights from July 1994 to April 1995

  1995cites this paper
• Recent advances in the pharmacological control of experimental allergic encephalomyelitis (EAE) and the implications for multiple sclerosis treatment

  1995cites this paper
• Molecular mechanisms in the control of translation by hormones and growth factors.

  1994cites this paper
• Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin.

  1994cites this paper
• Synthesis of secorapamycin esters and amides

  1994cites this paper
• Renal effects of rapamycin in the spontaneously hypertensive rat

  1994cites this paper
• Suppression of allograft responses by combining alloantigen-specific i.v. pre-sensitization with suboptimal doses of rapamycin.

  1994cites this paper
• Über Peptidyl‐Prolyl‐cis/trans‐Isomerasen und ihre Effektoren

  1994cites this paper
• Small bowel transplantation: an overview

  1994cites this paper
• Rapamycin, a potent inhibitor of T-cell function, prevents graft rejection in murine recipients of allogeneic T-cell-depleted donor marrow.

  1994cites this paper
• Prophylaxis and treatment of acute graft-versus-host disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high-risk patients.

  1994cites this paper
• EFFECTS OF RAPAMYCIN ON RENAL HEMODYNAMICS, WATER AND SODIUM EXCRETION, AND PLASMA LEVELS OF ANGIOTENSIN II, ALDOSTERONE, ATRIAL NATRIURETIC PEPTIDE, AND VASOPRESSIN IN PIGS

  1994cites this paper
• Rapamycin inhibits corneal allograft rejection and neovascularization.

  1994cites this paper
• Ring expanded rapamycin derivatives

  1994cites this paper
• Transplantation immunology.

  1994cites this paper
• Cyclosporin A does not affect the absolute rate of cortical bone resorption at the organ level in the growing rat

  1994cites this paper
• Horizons in pharmacologic intervention in allergic contact dermatitis.

  1994cites this paper
• SUPPRESSION OF ALLOGRAFT RESPONSES BY COMBINING DONOR ALLOANTIGEN‐SPECIFIC INTRAVENOUS PRESENSITIZATION WITH SUBOPTIMAL DOSES OF FK506

  1993cites this paper
• Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome.

  1993cites this paper
• The new antibody technologies.

  1993cites this paper
• [FK506: an immunosuppressor for the '90's?].

  1993cites this paper
• Inhibition by rapamycin of leukocyte migration and bronchial hyperreactivity induced by injection of Sephadex beads to guinea‐pigs

  1993cites this paper
• Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity.

  1993cites this paper
• Prevention and Treatment of Allograft Rejection in Vivo by Rapamycin: Molecular and Cellular Mechanisms of Action

  1993cites this paper
• Divergent effects of rapamycin on mouse and rat cells following mitogenic stimulation.

  1993cites this paper
• Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations

  1993cites this paper
• Effects of Orally Administered Rapamycin in Animal Models of Arthritis and Other Autoimmune Diseases

  1993cites this paper
• Rapamycin, a potential disease-modifying antiarthritic drug.

  1993cites this paper
• Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile.

  1993cites this paper
• Rapamycin Prolongs Survival of Murine Recipients of Fully Allogeneic Donor Grafts When Administered during the Graft‐versus‐Host Disease Process a

  1993cites this paper
• RESPONSIVENESS OF PREACTIVATED B CELLS TO IL‐2 AND IL‐6 EFFECT OF CYCLOSPORINE AND RAPAMYCIN

  1993cites this paper
• Rapamycin: In Vitro Profile of a New Immunosuppressive Macrolide.

  1993cites this paper
• Immunomodulating drugs: major advances in research and development.

  1993cites this paper
• Drugs acting on the intracellular signalling system

  1993cites this paper
• EVIDENCE THAT RAPAMYCIN HAS DIFFERENTIAL EFFECTS ON IL‐4 FUNCTION: MULTIPLE IL‐4 SIGNALING PATHWAYS AND IMPLICATIONS FOR IN VIVO USE

  1993cites this paper
• Rapamycin inhibits lymphocyte proliferation in a popliteal lymph node model via an IL-2-independent mechanism.

  1993cites this paper
• Structure-activity studies of nonmacrocyclic rapamycin derivatives

  1993cites this paper
• Patent Update: Anti-inflammatory Patent Highlights from the Second Half of 1992

  1993cites this paper
• Rapamycin's Inhibition Lymphocyte Proliferation in a Poplked Lymph Node Model via an IL‐2‐Independent Mechanism

  1993cites this paper
• Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

  1993cites this paper
• Immunomodulating Drugs: Major Advances in Research and Development

  1993cites this paper
• Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides

  1992cites this paper